Daiichi Sankyo Unit Seeks $178M From Novartis As Trial Ends
Daiichi Sankyo subsidiary's counsel told a California federal jury during trial closings Wednesday that Novartis owes more than $177.8 million in royalties and fixed payments for infringing its skin cancer treatment...To view the full article, register now.
Already a subscriber? Click here to view full article